PDSB today
$0.88-$0.10 (-10.56%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns down below $0.20
Key levels
Resistance$1.15
Resistance$0.90
Support$0.62
Support$0.26
Latest news & SEC filings
EarningsPDS Biotechnology posts quarterly loss of $0.11 per share, wider than expected
SEC FilingPDS Biotechnology Corp filed a report on a major company event (Form 8-K)
DealPDS Biotechnology says NantWorks exercised warrants for $3.9 million
All PDSB news →About PDS Biotechnology
PDS Biotechnology is an immunotherapy firm whose drug candidates are still in testing and have not yet been approved. Its main technology, Versamune, is paired with disease-related proteins to prompt immune responses, and its lead candidate PDS0101 targets HPV-linked cancers such as head and neck and cervical tumors. The company also works on Infectimune for preventive vaccines and on PDS01ADC, an IL-12 antibody conjugate, often combining these with other cancer treatments. Studies are run by the company and by outside research centers.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
PDS Biotechnology Corp (PDSB)
What Is the Price Target for PDSB?
SEPT Low Target
$4.00
SEPT Mid Target
$4.50
SEPT High Target
$5.00
Analyst Consensus
$4.50
Is PDSB a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PDSB.
Start Free Trial →Is PDSB Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$4.50
2
Moat Score
NONE
2/9
Piotroski Score
-11.3
Altman Z-Score
What Is Smart Money Doing with PDSB?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PDSB Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
28.16%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for PDSB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PDSB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:28:05 | $0.87 | 2,000 | $$2K | SELL |
| 20:26:15 | $0.88 | 1,000 | $$879 | BUY |
| 20:21:45 | $0.87 | 1,000 | $$872 | SELL |
| 20:19:39 | $0.88 | 5,000 | $$4K | BUY |
| 20:19:33 | $0.88 | 10,000 | $$9K | BUY |
5 dark pool trades shown · $$17K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for PDSB
PREVIEWSEPT Investing provides real-time options flow tracking for PDSB, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $0.5 | May 21 | 189 | $$5250 | 105 | BLOCK |
| PUT | $1 | Nov 27 | 14 | $$160 | 8 | SWEEP |
| PUT | $1 | Nov 27 | 14 | $$160 | 8 | SWEEP |
| PUT | $1 | Nov 27 | 14 | $$80 | 4 | SWEEP |
| CALL | $1 | Nov 20 | 7 | $$240 | 48 | SWEEP |
5 options trades shown · 40% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About PDSB
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for PDSB. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$pdsb filed an 8-k on tue nov 10: nantworks exercised warrants for 17,699,115 shares at $0.22 per share, about $3.9 million gross proceeds.
Join 3,500+ traders discussing PDSB in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for PDS Biotechnology Corp (PDSB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PDSB — frequently asked questions
What is PDSB stock price today?
PDS Biotechnology Corp (PDSB) is at $0.88, down 10.56% (-$0.10) at the Nov 13, 2026 close.
Why is PDSB stock moving today?
Latest PDSB news — Nov 13, 2026: PDS Biotechnology posts quarterly loss of $0.11 per share, wider than expected · Nov 13, 2026: PDS Biotechnology Corp filed a report on a major company event (Form 8-K)
What is the PDSB price target?
The average analyst price target for PDSB is $4.50, ranging from $4 to $5, based on 2 analysts.
What do analysts rate PDSB?
Analyst ratings for PDSB: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did PDSB beat earnings?
PDSB last reported on Aug 13, 2026: EPS -$0.18 vs -$0.13 expected — a miss of 38.5%.
Does PDSB pay a dividend?
PDSB does not currently pay a dividend.
What are PDSB support and resistance levels?
Support: $0.62, $0.26. Resistance: $0.90, $1.15, $1.35.
What are insiders doing with PDSB?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on PDSB?
Nov 13, 2026: PDS Biotechnology posts quarterly loss of $0.11 per share, wider than expected · Nov 13, 2026: PDS Biotechnology Corp filed a report on a major company event (Form 8-K) · Nov 11, 2026: PDS Biotechnology says NantWorks exercised warrants for $3.9 million